Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

@article{Lv2014CodeliveryOD,
  title={Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.},
  author={Shixian Lv and Zhaohui Tang and Mingqiang Li and Jian Lin and Wantong Song and Huaiyu Liu and Yubin Huang and Yuanyuan Zhang and Xuesi Chen},
  journal={Biomaterials},
  year={2014},
  volume={35 23},
  pages={
          6118-29
        }
}
Despite progress, combination therapy of different functional drugs to increase the efficiency of anticancer treatment still remains challenges. An amphiphilic methoxy poly(ethylene glycol)-b-poly(l-glutamic acid)-b-poly(l-lysine) triblock copolymer decorated with deoxycholate (mPEsG-b-PLG-b-PLL/DOCA) was synthesized and developed as a nanovehicle for the co-delivery of anticancer drugs: doxorubicin (DOX) and paclitaxel (PTX). The amphiphilic copolymer spontaneously self-assembled into micellar… Expand
Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
TLDR
It can be concluded that core-shell-corona nanoparticles prepared by PCL-b-PGlu-g-mPEG could be a promising co-delivery system for drug combination therapy in the treatment of breast cancer. Expand
A poly(ascorbyl acrylate)-containing nanoplatform with anticancer activity and the sequential combination therapy with its loaded paclitaxel.
TLDR
In vitro cytotoxicity assays against normal cell line NIH3T3 and breast cancer cell line MCF-7 demonstrated that PAA-b-PLA/Mal-PEG- b-PLA complex nanoparticles exhibited benign biocompatibility against normal cells and prominent cancer inhibition ability. Expand
Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer
TLDR
Co-delivery of cisplatin and paclitaxel by FA-PEG-PLGA nanoparticles results in more effective antitumor effects than the combination of free-drugs or single-drug-loaded nanoparticles. Expand
Biocompatibility and paclitaxel/cisplatin dual-loading of nanotubes prepared from poly(ethylene glycol)-polylactide-poly(ethylene glycol) triblock copolymers for combination cancer therapy
TLDR
It is concluded that PEG-PLA-PEG nanotubes with outstanding biocompatibility could be promising for co-delivery of hydrophilic and hydrophobic agents in combination cancer therapy. Expand
Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
TLDR
In vivo studies revealed that the combination chemotherapy of polymersomes to BEL-7404 xenograft tumor via intravenous injection was superior to free drug cocktail treatment, and the FA-targeted Co-PS exhibited significantly higher tumor growth inhibition than non-targeting Co- PS group. Expand
Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro.
TLDR
The NPDOX+CQ constructed in this study provides a feasible strategy for reversing MDR in tumour cells and can prevent the drug from being recognised and excluded by P-gp, and CQ blocks the process of autophagy so that the DOX is protected and more distributed to the nucleus of multidrug resistance (MDR) cell. Expand
Preparation and evaluation of PCL-PEG-PCL polymeric nanoparticles for doxorubicin delivery against breast cancer
Doxorubicin (DOX), an anthracycline anticancer drug, was successfully incorporated into polymeric nanoparticles (NPs) based on poly(e-caprolactone)–poly(ethylene glycol)–poly(e-caprolactone)Expand
Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect
TLDR
In vivo investigation on NSCLC animal models showed that co-delivery of PTX and DOX possessed high tumor-targeting capacity and strong anti-tumor activity, and the PTX-DOX NLC offered an effective strategy for targeted combinational lung cancer therapy. Expand
Efficient Co-delivery of Doxorubicin and Methotrexate by pH-Sensitive Dual-Functional Nanomicelles for Enhanced Synergistic Antitumor Efficacy
Combination therapy by co-delivering multiple drugs using a single delivery carrier is a promising strategy to achieve a synergistic antitumor effect. In this study, a novel dual-functional blockExpand
Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)–poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy
TLDR
Co-delivery of PTX and GEM by methoxy poly(ethylene glycol)–poly(lactide-coglycolide) might have important potencies in clinical applications for breast cancer therapy and shows enhanced anticancer effects and reduced systemic toxicity in vivo compared with free drugs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
TLDR
In vivo studies on the subcutaneous non-small cell lung cancer (A549) xenograft nude mice model confirmed that DOX-NP showed significant antitumor activity and reduced side effects, and then enhanced tumor accumulation as a result of the prolonged circulation in blood and the enhanced permeation and retention effect, indicating its great potential for cancer therapy. Expand
Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
TLDR
The results demonstrated that mPEG-b-PLG was a promising vector to deliver DOX·HCl into tumors and achieve improved pharmacokinetics, biodistribution and efficacy of DOX-HCl with reduced toxicity. Expand
Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
The use of single chemotherapeutic drug has shown some limitations in anti-tumor treatment, such as development of drug resistance, high toxicity and limited regime of clinical uses. The combinationExpand
Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy in vitro.
TLDR
The results indicated that the biocompatible reduction-responsive micelles have vast potential in targeted intracellular delivery of antitumor drugs to achieve enhanced efficacy in malignancy therapy. Expand
Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
TLDR
Results suggest that H40-P(LA-DOX)-b-PEG-OH/FA micelles could be a promising nanocarrier with excellent in vivo stability for targeting the drugs to cancer cells and releasing the drug molecules inside the cells by sensing the acidic environment of the endosomal compartments. Expand
Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform.
TLDR
The drug-loaded polymersomes exhibit the enhanced therapeutic efficacy, increase apoptosis in tumor tissues, and reduce systemic toxicity in nude mice bearing A549 lung cancer xenograft, in comparison with free DOX ·HCl. Expand
Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.
TLDR
A tailor-made dual pH-sensitive polymer-drug conjugate nanoparticulate system has showed enhanced cytotoxicity in drug-resistant cancer stem cells, indicating its great potential for cancer therapy. Expand
Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram.
TLDR
The smart co-delivery system was very effective in enhancing the cytotoxicity by increasing the intracellular accumulation of DOX and promoting the apoptotic response, and showed the most effective inhibitory effect on the growth of drug-resistant breast cancer xenografts as compared to other combinations of both drugs. Expand
Doxil®--the first FDA-approved nano-drug: lessons learned.
  • Y. Barenholz
  • Medicine
  • Journal of controlled release : official journal of the Controlled Release Society
  • 2012
TLDR
This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use and demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles. Expand
Preparation of photo-cross-linked pH-responsive polypeptide nanogels as potential carriers for controlled drug delivery
Diblock and triblock copolymers, including poly(ethylene glycol monomethyl ether)-b-poly(L-glutamic acid-co-γ-cinnamyl-L-glutamate) (mPEG-b-P(LGA/CLG)) and poly(L-glutamicExpand
...
1
2
3
4
...